FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809989268> ?p ?o ?g. }

• W2809989268 endingPage "31" @default.
• W2809989268 startingPage "22" @default.
• W2809989268 abstract "Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding transthyretin ( TTR) that induce transthyretin misfolding and systemic deposition of amyloid. Progressive amyloid accumulation leads to multiorgan dysfunction and death. Inotersen, a 2'- O-methoxyethyl-modified antisense oligonucleotide, inhibits hepatic production of transthyretin.We conducted an international, randomized, double-blind, placebo-controlled, 15-month, phase 3 trial of inotersen in adults with stage 1 (patient is ambulatory) or stage 2 (patient is ambulatory with assistance) hereditary transthyretin amyloidosis with polyneuropathy. Patients were randomly assigned, in a 2:1 ratio, to receive weekly subcutaneous injections of inotersen (300 mg) or placebo. The primary end points were the change in the modified Neuropathy Impairment Score+7 (mNIS+7; range, -22.3 to 346.3, with higher scores indicating poorer function; minimal clinically meaningful change, 2 points) and the change in the score on the patient-reported Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating poorer quality of life). A decrease in scores indicated improvement.A total of 172 patients (112 in the inotersen group and 60 in the placebo group) received at least one dose of a trial regimen, and 139 (81%) completed the intervention period. Both primary efficacy assessments favored inotersen: the difference in the least-squares mean change from baseline to week 66 between the two groups (inotersen minus placebo) was -19.7 points (95% confidence interval [CI], -26.4 to -13.0; P<0.001) for the mNIS+7 and -11.7 points (95% CI, -18.3 to -5.1; P<0.001) for the Norfolk QOL-DN score. These improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy. There were five deaths in the inotersen group and none in the placebo group. The most frequent serious adverse events in the inotersen group were glomerulonephritis (in 3 patients [3%]) and thrombocytopenia (in 3 patients [3%]), with one death associated with one of the cases of grade 4 thrombocytopenia. Thereafter, all patients received enhanced monitoring.Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis. Thrombocytopenia and glomerulonephritis were managed with enhanced monitoring. (Funded by Ionis Pharmaceuticals; NEURO-TTR ClinicalTrials.gov number, NCT01737398 .)." @default.
• W2809989268 created "2018-07-10" @default.
• W2809989268 creator A5007252463 @default.
• W2809989268 creator A5007490829 @default.
• W2809989268 creator A5008831230 @default.
• W2809989268 creator A5011018483 @default.
• W2809989268 creator A5011566295 @default.
• W2809989268 creator A5012884078 @default.
• W2809989268 creator A5014037430 @default.
• W2809989268 creator A5014057757 @default.
• W2809989268 creator A5015330548 @default.
• W2809989268 creator A5028643716 @default.
• W2809989268 creator A5031336726 @default.
• W2809989268 creator A5033586858 @default.
• W2809989268 creator A5038371805 @default.
• W2809989268 creator A5039227038 @default.
• W2809989268 creator A5040530313 @default.
• W2809989268 creator A5043229467 @default.
• W2809989268 creator A5043674134 @default.
• W2809989268 creator A5044334898 @default.
• W2809989268 creator A5051132104 @default.
• W2809989268 creator A5054830306 @default.
• W2809989268 creator A5056200724 @default.
• W2809989268 creator A5061857871 @default.
• W2809989268 creator A5064165672 @default.
• W2809989268 creator A5065854605 @default.
• W2809989268 creator A5070359355 @default.
• W2809989268 creator A5072181166 @default.
• W2809989268 creator A5074880309 @default.
• W2809989268 creator A5082591664 @default.
• W2809989268 creator A5084097469 @default.
• W2809989268 creator A5084816017 @default.
• W2809989268 creator A5085821633 @default.
• W2809989268 creator A5086018261 @default.
• W2809989268 creator A5088842832 @default.
• W2809989268 creator A5089060660 @default.
• W2809989268 creator A5091001804 @default.
• W2809989268 date "2018-07-05" @default.
• W2809989268 modified "2023-10-12" @default.
• W2809989268 title "Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis" @default.
• W2809989268 cites W1705652151 @default.
• W2809989268 cites W1980144587 @default.
• W2809989268 cites W1991876073 @default.
• W2809989268 cites W2004563081 @default.
• W2809989268 cites W2009082034 @default.
• W2809989268 cites W2011246655 @default.
• W2809989268 cites W2018281939 @default.
• W2809989268 cites W2078522982 @default.
• W2809989268 cites W2115862827 @default.
• W2809989268 cites W2117942418 @default.
• W2809989268 cites W2122861669 @default.
• W2809989268 cites W2131999691 @default.
• W2809989268 cites W2148373528 @default.
• W2809989268 cites W2148937629 @default.
• W2809989268 cites W2153026275 @default.
• W2809989268 cites W2160966221 @default.
• W2809989268 cites W2161648900 @default.
• W2809989268 cites W2473426008 @default.
• W2809989268 cites W2473879127 @default.
• W2809989268 cites W2583673989 @default.
• W2809989268 cites W2626332910 @default.
• W2809989268 cites W2684293987 @default.
• W2809989268 cites W2706854482 @default.
• W2809989268 cites W2739898475 @default.
• W2809989268 cites W2769583052 @default.
• W2809989268 cites W4249657562 @default.
• W2809989268 doi "https://doi.org/10.1056/nejmoa1716793" @default.
• W2809989268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29972757" @default.
• W2809989268 hasPublicationYear "2018" @default.
• W2809989268 type Work @default.
• W2809989268 sameAs 2809989268 @default.
• W2809989268 citedByCount "889" @default.
• W2809989268 countsByYear W28099892682018 @default.
• W2809989268 countsByYear W28099892682019 @default.
• W2809989268 countsByYear W28099892682020 @default.
• W2809989268 countsByYear W28099892682021 @default.
• W2809989268 countsByYear W28099892682022 @default.
• W2809989268 countsByYear W28099892682023 @default.
• W2809989268 crossrefType "journal-article" @default.
• W2809989268 hasAuthorship W2809989268A5007252463 @default.
• W2809989268 hasAuthorship W2809989268A5007490829 @default.
• W2809989268 hasAuthorship W2809989268A5008831230 @default.
• W2809989268 hasAuthorship W2809989268A5011018483 @default.
• W2809989268 hasAuthorship W2809989268A5011566295 @default.
• W2809989268 hasAuthorship W2809989268A5012884078 @default.
• W2809989268 hasAuthorship W2809989268A5014037430 @default.
• W2809989268 hasAuthorship W2809989268A5014057757 @default.
• W2809989268 hasAuthorship W2809989268A5015330548 @default.
• W2809989268 hasAuthorship W2809989268A5028643716 @default.
• W2809989268 hasAuthorship W2809989268A5031336726 @default.
• W2809989268 hasAuthorship W2809989268A5033586858 @default.
• W2809989268 hasAuthorship W2809989268A5038371805 @default.
• W2809989268 hasAuthorship W2809989268A5039227038 @default.
• W2809989268 hasAuthorship W2809989268A5040530313 @default.
• W2809989268 hasAuthorship W2809989268A5043229467 @default.
• W2809989268 hasAuthorship W2809989268A5043674134 @default.
• W2809989268 hasAuthorship W2809989268A5044334898 @default.
• W2809989268 hasAuthorship W2809989268A5051132104 @default.

• next